Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826978 | 1.00 | PIK3CD (0.36) | PIK3CDPIK3CAPIK3CGAAK1MAP4K1 | |
| SCHEMBL26906357 | 0.84 | KDM4E (0.35) | PIK3CDPIK3CAPIK3CG | |
| SCHEMBL26906242 | 0.84 | PIK3CD (0.34) | PIK3CDPIK3CAPIK3CGAAK1MAP4K1 | |
| SCHEMBL26906201 | 0.81 | SIK1 (0.40) | PIK3CDPIK3CAPIK3CGALOX5APFEN1 | |
| SCHEMBL26906189 | 0.78 | MAP4K1 (0.44) | PIK3CDPIK3CAPIK3CGMAP4K1ABL1 | |
| SCHEMBL26906190 | 0.78 | MAP4K1 (0.37) | PIK3CDPIK3CAPIK3CGMAP4K1ALOX5AP | |
| SCHEMBL29826973 | 0.78 | MAP4K1 (0.37) | PIK3CDPIK3CAPIK3CGMAP4K1ALOX5AP | |
| SCHEMBL26906135 | 0.78 | PIK3CA (0.35) | PIK3CDPIK3CAPIK3CGAAK1ALOX5AP | |
| SCHEMBL29826759 | 0.77 | MAPK10 (0.40) | PIK3CAMAP4K1MAPK10 | |
| SCHEMBL26906161 | 0.77 | MAPK10 (0.40) | PIK3CAMAP4K1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022165529-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | PIK3CD 430/4885PIK3CA 502/4885PIK3CG 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.